Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study
Clin Cancer Res
.
2023 Nov 14;29(22):4698.
doi: 10.1158/1078-0432.CCR-23-2993.
Authors
Andrea Wang-Gillam
,
Kian-Huat Lim
,
Robert McWilliams
,
Rama Suresh
,
Albert C Lockhart
,
Amberly Brown
,
Marcus Breden
,
Jad I Belle
,
John Herndon
,
Savannah J Bogner
,
Katrina Pedersen
,
Benjamin Tan
,
Nicholas Boice
,
Abhi Acharya
,
Mina Abdiannia
,
Feng Gao
,
Harry H Yoon
,
Mojun Zhu
,
Nikolaos A Trikalinos
,
Lee Ratner
,
Olivia Aranha
,
William G Hawkins
,
Brett H Herzog
,
David G DeNardo
PMID:
37960920
DOI:
10.1158/1078-0432.CCR-23-2993
No abstract available
Publication types
Published Erratum